Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Accumulated Expenses (2020 - 2025)

Historic Accumulated Expenses for Rani Therapeutics Holdings (RANI) over the last 6 years, with Q3 2025 value amounting to $2.1 million.

  • Rani Therapeutics Holdings' Accumulated Expenses rose 1199.79% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year increase of 1199.79%. This contributed to the annual value of $2.1 million for FY2024, which is 2010.43% up from last year.
  • Rani Therapeutics Holdings' Accumulated Expenses amounted to $2.1 million in Q3 2025, which was up 1199.79% from $2.6 million recorded in Q2 2025.
  • Rani Therapeutics Holdings' Accumulated Expenses' 5-year high stood at $4.4 million during Q3 2022, with a 5-year trough of $1.4 million in Q4 2021.
  • Its 5-year average for Accumulated Expenses is $2.7 million, with a median of $2.5 million in 2024.
  • As far as peak fluctuations go, Rani Therapeutics Holdings' Accumulated Expenses soared by 16072.73% in 2021, and later tumbled by 5249.36% in 2024.
  • Rani Therapeutics Holdings' Accumulated Expenses (Quarter) stood at $1.4 million in 2021, then skyrocketed by 63.81% to $2.3 million in 2022, then decreased by 26.52% to $1.7 million in 2023, then grew by 20.1% to $2.1 million in 2024, then rose by 0.87% to $2.1 million in 2025.
  • Its Accumulated Expenses was $2.1 million in Q3 2025, compared to $2.6 million in Q2 2025 and $2.3 million in Q1 2025.